Kisspeptin is a naturally occurring signaling peptide involved in reproductive hormone control. Kisspeptin-10 and kisspeptin-54 have been studied in humans, but neither is an FDA-approved treatment in the United States.
Kisspeptin at a glance
| What it is | A family of peptides produced from the KISS1 gene that activate the KISS1 receptor |
|---|---|
| Forms in research | Kisspeptin-10 and kisspeptin-54 are distinct fragments and should not be treated as interchangeable |
| Human evidence | Experimental studies in reproductive endocrinology, IVF, hypogonadism, and sexual-behavior research |
| U.S. status | No FDA-approved kisspeptin drug identified |
| Reviewed | August 11, 2026 |
What does kisspeptin do?
Kisspeptin signaling helps regulate gonadotropin-releasing hormone, which influences luteinizing hormone and follicle-stimulating hormone. That biology makes kisspeptin scientifically relevant to puberty, fertility, and reproductive endocrine disorders. A plausible mechanism, however, is not the same as proof that an online product safely treats low testosterone, infertility, or sexual dysfunction.
What has human research found?
Small controlled physiology studies show that kisspeptin-10 can stimulate luteinizing hormone secretion in men. Research involving kisspeptin-54 has also explored oocyte maturation during IVF and brain responses related to sexual desire. These studies used defined research preparations, selected participants, intensive monitoring, and narrow outcomes. They do not validate unsupervised commercial products or establish routine treatment protocols.
Kisspeptin-10 is not the same as kisspeptin-54
Online discussions often shorten every form to “kisspeptin.” The fragments differ in length, pharmacology, and the evidence attached to them. Results from a kisspeptin-54 IVF study cannot automatically be transferred to kisspeptin-10 sold for another purpose.
Safety and product-quality uncertainties
FDA’s compounding review states that kisspeptin-10 is not a component of an FDA-approved drug and identified potential immunogenicity, peptide-impurity, and active-ingredient characterization concerns for compounded products. Effects on reproductive hormones also make the user’s underlying condition, fertility goals, pregnancy potential, and other hormone-active medicines important clinical context.
What people report online
Community-reported—not proof: posts commonly discuss libido, testosterone, fertility, mood, or combinations with other hormone-related compounds. Product identity, laboratory testing, baseline hormone status, concurrent medicines, and expectancy effects are usually unclear, so anecdotes cannot establish cause or safety.
Bottom line
Kisspeptin has real human research behind its reproductive biology, but the evidence is indication-specific and does not turn retail kisspeptin products into established therapies. The most important distinctions are the exact peptide form, the studied population, the measured outcome, and whether the product itself was independently characterized.
Primary sources
- Kisspeptin-10 human luteinizing-hormone study
- Kisspeptin-10 study in men with type 2 diabetes and mild biochemical hypogonadism
- Kisspeptin-54 phase 2 IVF study
- Randomized kisspeptin-54 study in women with hypoactive sexual desire disorder
- FDA briefing document on kisspeptin-10
Educational evidence review only. This article does not provide dosing, injection, fertility, hormone, or treatment instructions.
Leave a Reply